Research programme: small molecule therapeutics - Almai Biotechnology/Simcere Pharmaceutical Group
Latest Information Update: 04 Feb 2021
At a glance
- Originator Almai Biotechnology; Simcere Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer; CNS disorders